Ara Dickran Metjian

Instructor in the Department of Medicine

Medicine, Hematology

ara.metjian@duke.edu

Duke Box 3422, Duke University Medical Center, Durham, NC 27710

0547 Stead Building, 100 Trent Drive, Durham, NC 27710

More About This Person

At a Glance

Credentials
1. Education
2. Training & Certifications

Academic Experience
1. Current Appointments & Affiliations
2. Previous Appointments & Affiliations

Expertise

Research
1. Selected Grants

Publications
1. Selected Publications

Artistic Works / Events

Teaching

Advising & Mentoring

Recognition

Professional Activities

Embed Profile Data

Embed Profile Data

Selected Grants

Hematology & Transfusion Medicine (T32)

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1975 - 2026

Prospective Randomized open blinded end-point (PROBE) study

Clinical TrialPrincipal Investigator · Awarded by Baim Institute for Clinical Research · 2018 - 2021

Phase IV open label study of Emicizumab Prophylaxis in Hemophila A patients undergoing minor surgery

Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2018 - 2020

Edoxaban in VTE Associated with Cancer Hokusai VTE Cancer Study DU176b-D-U311

Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2015 - 2020

An open-label, multicenter, Post-Marketing Requirement study to investigate the safety and tolerability of octaplas in the management of pediatric patients who require therapeutic plasma exchange

Clinical TrialPrincipal Investigator · Awarded by Octapharma AG · 2017 - 2019

ART Study (Rituximab as adjunct therapy with plasma exchange in TTP patients)

Clinical TrialPrincipal Investigator · Awarded by Washington University School of Medicine · 2015 - 2019

Microfluidic quartz resonator based blood plasma coagulation monitors

ResearchCollaborator · Awarded by Qatch Technologies LLC · 2017 - 2018

A Phase III Trial with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Clinical TrialPrincipal Investigator · Awarded by Ablynx · 2016 - 2017

RE-VERSE-AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial

Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2015 - 2017

Public Health Surveillance of Bleeding

ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2011 - 2016

A randomized, blinded, placebo-controlled, dose finding study to assess the safety and efficacy of the oral thrombopoietin receptor agonist, eltrombopag, administered to subjects with acute myelogenous leukaemia (AML) receiving induction chemotherapy

Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2013 - 2016